Polyfunctional Melan-A-specific tumor-reactive CD8⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS

Ornella FranzeseDepartment of Systems Medicine, University of Tor Vergata, Rome, Italy

Belinda PalermoDepartment of Molecular Medicine, University of Rome “La Sapienza;” Rome, Italy;Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy

Cosmo Di DonnaDepartment of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy

Isabella SperdutiBiostatistics and Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy

Virginia FerraresiDepartment of Experimental Oncology, Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy

Helena StabileDepartment of Molecular Medicine, University of Rome “La Sapienza;” Rome, Italy

Angela GismondiDepartment of Molecular Medicine, University of Rome “La Sapienza;” Rome, Italy

Angela SantoniDepartment of Molecular Medicine, University of Rome “La Sapienza;” Rome, Italy

Paola NisticòDepartment of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, ItalyCorrespondence[email protected].

show all

Polyfunctional Melan-A-specific tumor-reactive CD8⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS

Supplementary Files

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Polyfunctional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS

Supplementary Files

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Polyfunctional Melan-A-specific tumor-reactive CD8⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS